Global Alzheimer’s Therapeutics Market Is Expected To Reach USD 14,856.3 Mn By 2022 | Credence Research

The latest market report published by Credence Research, Inc. “Global Alzheimer’s Therapeutics Market – Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 – 2022,” the Alzheimer’s therapeutics market was valued at USD 8.524.9 million in 2015 and is expected to reach USD 14.856.3 million by 2022, increasing to CAGR by 8.02 percent from 2016 to 2022.

Market Insights

Alzheimer’s disease is a progressive and currently incurable disease, and potential or supportive treatment has only emerged in the last decade. However, there is a lack of currently available treatments in terms of efficacy or target specificity. There are two types of drug classes used in the treatment of Alzheimer’s disease, acetylcholinesterase (ACE) inhibitors, and N-methyl-D-aspartate (NMDA) receptor antagonists. ACE inhibitors are galantamine hydrochloride, dopezil hydrochloride, and rivastigmine; the NMDA receptor antagonist includes mematidine hydrochlorides.

Browse Full Report Originally Published by Credence Research at https://www.credenceresearch.com/report/alzeimers-therapeutic-market

Since the discovery of the plates and tangles of Alzheimer’s –amyloid β (Aβ) peptide and hyperphosphorylated tau (p-tau) protein, respectively. Immense research and development have been carried out to develop therapeutics that can reduce the rate of synthesis, reduce toxicity or eliminate these factors from the brain. These attempts have, however, been largely unsuccessful. Thus, given the ever-increasing Alzheimer’s prevalent population, as well as the limited drugs available for treatment, Alzheimer’s disease offers a lucrative opportunity for effective disease-modifying therapy to enter the market.

Pipeline Analysis

The phase III drugs included in the pipeline analysis are ENA713 (Novartis Pharmaceuticals), Flutemetamol (18F) (GE Healthcare), LY450139 (Eli Lilly and Company), Dimebon (Medivation, Inc. & Pfizer, Inc.), and Aripiprazole/ BMS-337039 (Otsuka Pharmaceutical, Inc.). The overall pipeline for Alzheimer’s is still very much dominated by small molecule drugs. However, there is still a considerable number of biologics in the pipeline with a total 86 molecules, represented across all stages of development. According to market experts, the diversity of the several molecule types in the biologic group shows a certain level of innovation, with newer avenues being explored in accounts of recent failures. Overall, late-stage clinical trials have highlighted very few molecules that could potentially replace current treatments during the forecast period.

Key Market Movements:

  • Market experts suggest that a family history of Alzheimer’s increases the risk of disease development by 7.5 times
  • The incidence and prevalence of Alzheimer’s disease doubles every five years  after age 65 years
  • Currently, the population of developed countries is at high risk of Alzheimer due to increasing geriatric population
  • In developing countries from the Asia Pacific and Latin America, the awareness related to age-specific diseases such as dementia or Alzheimer is increasing

Access Free Sample Copy of Research Report: https://www.credenceresearch.com/sample-request/57811

Market Segmentation

By Drug Type

  • Memantine Hydrochloride
  • Donepezil Hydrochloride
  • Rivastigmine
  • Galantamine Hydrobromide

By Geography Segment Type

  • North America (the U.S., Rest of North America)
  • Europe (U.K., Germany, France, Rest of Europe)
  • Asia Pacific (China, Japan, India, Rest of Asia Pacific)
  • Rest of the World (the Middle East & Africa, Latin America)

Access Free Sample Copy of Research Report: https://www.credenceresearch.com/sample-request/57811

Medium Blog: Alzheimer’s Therapeutics Market